Related Experiment Video
Updated: Jan 14, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Toward Regulatory Convergence and Streamlined Biosimilar Development: Recommendations from an International
Elif Car1, Liese Barbier1, Ingrid Schwarzenberger2
1Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
Stakeholders identified key recommendations to streamline biosimilar development and achieve global regulatory convergence. These include enhancing education, promoting reliance, and aligning requirements for faster drug approval.
Area of Science:
- Pharmaceutical Sciences
- Regulatory Science
- Biotechnology
Background:
- Biosimilar development faces scientific and regulatory hurdles globally.
- Demonstrating biosimilarity requires robust scientific evidence and clear regulatory pathways.
- International regulatory convergence is crucial for efficient biosimilar market access.
Purpose of the Study:
- To assess stakeholder perspectives on challenges in biosimilarity demonstration.
- To develop consensus-based recommendations for global regulatory convergence.
- To streamline the development process for biosimilars.
Main Methods:
- Modified Nominal Group Technique employed with international experts.
- Three-phase approach: individual grading, focus group discussions, and final grading.
- High consensus defined as ≥80% agreement and a weighted mean score of ≥4.0.
Main Results:
- 16 out of 22 consensus-based recommendations achieved high agreement.
- Top recommendations focus on education, regulatory reliance, and aligning requirements.
- Key proposals include reconsidering clinical efficacy studies and eliminating animal studies.
Conclusions:
- Consensus recommendations offer a roadmap for biosimilar development.
- Prioritizing these measures can foster regulatory convergence.
- Streamlining development will improve patient access to biosimilars.
More Related Videos
08:31Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
07:43Author Spotlight: Addressing Regulatory Gaps in Molecular Studies by Quantifying Viral Vectors in Complex Matrices
Published on: July 14, 2023
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Bioequivalence studies: Biowaivers
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Bioequivalence: Overview
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence